Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via unfolded protein response signaling

Oncotarget

Volumn 4, Issue 8, 2013, Pages 1212-1229

  Rico Bautista, Elizabeth ^a   Zhu, Wenhong ^a   Kitada, Shinichi ^a   Ganapathy, Suthakar ^b   Lau, Eric ^a   Krajewski, Stan ^a   Ramirez, Joel ^c   Bush, Jason A ^c   Yuan, Zhimin ^b,d   Wolf, Dieter A ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Mitochondrial function; Oxidative stress; Prostate cancer; Small molecule inhibitor

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYCLIN D1; N (4 BUTYL 2 METHYL PHENYL)ACETAMIDE; REACTIVE OXYGEN METABOLITE; SMIP 004; SMIP 004 7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; PROTEIN DEGRADATION; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE;

ACETAMIDES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN D1; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; UBIQUITIN; UNFOLDED PROTEIN RESPONSE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884318693     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1130     Document Type: Article

References (59)

1. Visvader JE: Cells of origin in cancer. Nature 2011, 469:314-322.
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
3. Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
4. Greaves M, Maley CC: Clonal evolution in cancer. Nature 2012, 481:306-313.
5. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM: Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012, 3:651-663.
6. Shen MM, Abate-Shen C: Molecular Genetics of Prostate Cancer: New Prospects for Old Challenges. Genes Dev 2010, 24:1967-2000.
7. Barbieri CE, Demichelis F, Rubin MA: Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012, 60:187-198.
8. Solimini NL, Luo J, Elledge SJ: Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells. Cell 2007, 130:986-988.
9. Luo J, Solimini NL, Elledge SJ: Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell 2009, 136:823-837.
10. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ: Mitogenic Signaling Mediated by Oxidants in Ras- Transformed Fibroblasts. Science 1997, 275:1649-1652.
11. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM: c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function: A Mechanism for Oncogene-Induced Genetic Instability. Molecular Cell 2002, 9:1031-1044.
12. Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria as targets for cancer chemotherapy. Seminars in Cancer Biology 2009, 19:57-66.
13. Ward PS, Thompson CB: Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell 2012, 21:297-308.
14. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Jagt DLV, Semenza GL, Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. PNAS 2010, 107:2037-2042.
15. Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S, Chen X: Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer Lett 2010, 298:176-185.
16. Rico-Bautista E, Yang C-C, Lu L, Roth GP, Wolf DA: Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostatecancer cells. BMC Biol 2010, 8:153.
17. Walter P, Ron D: The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation. Science 2011, 334:1081 -1086.
18. Fribley A, Zeng Q, Wang C-Y: Proteasome Inhibitor PS- 341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells. Molecular and Cellular Biology 2004, 24:9695 -9704.
19. Kim I, Xu W, Reed JC: Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nature Reviews Drug Discovery 2008, 7:1013-1030.
20. Tabas I, Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011, 13:184-190.
21. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
22. Zerbini LF, de Vasconcellos JF, Czibere A, Wang Y, Paccez JD, Gu X, Zhou J-R, Libermann TA: JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer. Cell Cycle 2011, 10:2583-2591.
23. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D: CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes & Development 1994, 8:453-464.
24. Chen M, Gutierrez GJ, Ronai ZA: Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control. PNAS 2011, 108:9119-9124.
25. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA: Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:8505.
26. Brewer JW, Diehl JA: PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proceedings of the National Academy of Sciences 2000, 97:12625.
27. Raven JF, Baltzis D, Wang S, Mounir Z, Papadakis AI, Gao HQ, Koromilas AE: PKR and PKR-like Endoplasmic Reticulum Kinase Induce the Proteasome-dependent Degradation of Cyclin D1 via a Mechanism Requiring Eukaryotic Initiation Factor 2a Phosphorylation. J Biol Chem 2008, 283:3097-3108.
28. Petroski MD, Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews Molecular Cell Biology 2005, 6:9-20.
29. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, et al.: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
30. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004, 10:33-39.
31. Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT: Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular cancer therapeutics 2009, 8:1340.
32. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N: 17-Allylamino-17- Demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/Neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin Cancer Res 2002, 8:986-993.
33. Lamoureux F, Thomas C, Yin M-J, Kuruma H, Fazli L, Gleave ME, Zoubeidi A: A novel HSP90 inhibitor delays castrate resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011, 17:2301-2313.
34. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H, Takahashi S, Kouzmenko A, Nohara K, Chiba T, Fujii-Kuriyama Y, Kato S: Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007, 446:562-566.
35. Ong S-E, Mann M: A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 2007, 1:2650-2660.
36. Li N: Mitochondrial Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production. Journal of Biological Chemistry 2002, 278:8516-8525.
37. Pelicano H: Inhibition of Mitochondrial Respiration: A novel strategy to enhance durg-induced apoptosis in human leukeia cells by a reactive oxygen species-mediated mechanism. Journal of Biological Chemistry 2003, 278:37832-37839.
38. Reichard JF, Motz GT, Puga A: Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucl Acids Res 2007, 35:7074-7086.
39. Barrientos A, Moraes CT: Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology. J Biol Chem 1999, 274:16188-16197.
40. Sharma A, Yeow W-S, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CES, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE: The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010, 120:4478-4492.
41. Nakayama K, Nagahama H, Minamishima YA, MatsumotoM, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, Kitagawa M, Nakayama K, Hatakeyama S: Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. The EMBO Journal 2000, 19:2069-2081.
42. Kim JK, Diehl JA: Nuclear cyclin D1: An oncogenic driver in human cancer. Journal of Cellular Physiology 2009, 220:292-296.
43. Henley SA, Dick FA: The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Division 2012, 7:10.
44. Zhang L, Wang C: F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006, 25:2615-2627.
45. Healy SJM, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A: Targeting the endoplasmic reticulum-stress response as an anticancer strategy. European Journal of Pharmacology 2009, 625:234-246.
46. Taguchi K, Motohashi H, Yamamoto M: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes to Cells 2011, 16:123-140.
47. Watson J: Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013, 3.
48. Malhotra JD, Kaufman RJ: Endoplasmic Reticulum Stress and Oxidative Stress: A Vicious Cycle or a Double-Edged Sword?. Antioxidants & Redox Signaling 2007, 9:2277-2294.
49. Wondrak GT: Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities. Antioxid Redox Signal 2009, 11:3013-3069.
50. Kong Q, Beel JA, Lillehei KO: A threshold concept for cancer therapy. Medical Hypotheses 2000, 55:29-35.
51. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison III B, Stockwell BR: Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell 2012, 149:1060-1072.
52. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475:231-234.
53. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang C-Y, Zhang M, Du Z, Barsoum J, Bertin J: Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008, 7:2319-2327.
54. Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE, Wada Y, Giaever G, Nislow C: Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol. PLoS ONE 2012, 7:e29798.
55. Yamaguchi Y, Larkin D, Lara-Lemus R, Ramos-Castañeda J, Liu M, Arvan P: Endoplasmic reticulum (ER) chaperone regulation and survival of cells compensating for deficiency in the ER stress response kinase, PERK. J Biol Chem 2008, 283:17020-17029.
56. Wu G, Feng X, Stein L: A human functional protein interaction network and its application to cancer data analysis. Genome biology 2010, 11:R53.
57. Brill LM, Motamedchaboki K, Wu S, Wolf DA: Comprehensive proteomic analysis of Schizosaccharomyces pombe by two-dimensional HPLC-tandem mass spectrometry. Methods 2009, 48:311-319.
58. Chintharlapalli S, Papineni S, Safe S: 1,1-Bis(3'-Indolyl)-1-(p-Substitutedphenyl)methanes Inhibit Growth, Induce Apoptosis, and Decrease the Androgen Receptor in LNCaP Prostate Cancer Cells Through Peroxisome Proliferator-Activated Receptor g-Independent Pathways. Mol Pharmacol 2007, 71:558-569.
59. Zu K, Bihani T, Lin A, Park YM, Mori K, Ip C: Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 2005, 25:546-554.